(Q35044577)

6 August 2017

1 reference

title

Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety (English)

1 reference

6 August 2017

0 references

0 references

1 reference

3

Jack Satsangi

1 reference

6 August 2017

Ian D R Arnott

1

1 reference

6 August 2017

David Watts

series ordinal

2

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

published in

Pharmacological Research

1 reference

6 August 2017

volume

47

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

1-10

1 reference

Inflammatory bowel disease: epidemiology and management in an English general practice population

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Prospective survey of childhood inflammatory bowel disease in the British Isles

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Incidence of juvenile-onset Crohn's disease in Scotland

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Smoking cessation and the course of Crohn's disease: an intervention study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

The clinical pharmacology of 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Hodgkin's disease after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

High incidence of secondary brain tumours after radiotherapy and antimetabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Inflammatory bowel disease is not associated with an increased risk of lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Inflammatory bowel disease and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Immunosuppressive drug use during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

TPMT in the treatment of Crohn's disease with azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Rational dosing of azathioprine and 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Tumor necrosis factor: biology and therapeutic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Biologic therapy of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Tumour-necrosis-factor antibody treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Infliximab in Crohn's disease: first anniversary clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Clinical experience with infliximab therapy in 100 patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Clinical use of Infliximab in Crohn's disease: the Edinburgh experience

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

NOD2/CARD15 does not influence response to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900264-5

7 January 2021

10.1016/S1043-6618(02)00264-5

Identifiers

DOI

1 reference

6 August 2017

1 reference